{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:06:41Z","timestamp":1781712401424,"version":"3.54.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Evidence-based Medicine Committee of Chinese Physicians Association","award":["KYS2021-03-02-2"],"award-info":[{"award-number":["KYS2021-03-02-2"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Tripterygium wilfordii multiglycosides has been demonstrated to be effective in reducing proteinuria and alleviate edema in patients with chronic kidney disease. We aim to evaluate its efficacy and safety in idiopathic membranous nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis:<\/jats:title>\n                    <jats:p>This is an randomized, open-labeled, controlled clinical trial. Twenty eligible patients with idiopathic membranous nephropathy will be randomly assigned into the intervention group and the control group at a rate of 1:1. Patients in the intervention group will receive tripterygium wilfordii multiglycosides tablets (1\u20131.5\u200amg\/kg body weight\/d, orally) in addition to the original treatment of angiotensin converting enzyme inhibitor\/angiotensin receptor blocker, while the control group will continue with the original treatment of angiotensin converting enzyme inhibitor\/angiotensin receptor blocker. The treatment course is 6 months, and clinical variables of patients will be measured at baseline and each monthly follow-up. The primary efficacy outcome measure is absolute decrease in urinary protein quantity after 6 months of treatment compared with baseline at randomization. The secondary efficacy outcome measures include absolute decrease in urine albumin-creatinine ratio in spot urine after 6 months of treatment compared with baseline at randomization, the percentage of patients who reached effective clinical response, and the percentage of patients who developed composite renal endpoint. Safety outcome measures include incidence of adverse events, incidence of serious adverse events, and death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000028842","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:04:37Z","timestamp":1644566677000},"page":"e28842","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of tripterygium wilfordii multiglycosides in idiopathic membranous nephropathy"],"prefix":"10.1097","volume":"101","author":[{"given":"Chanyu","family":"Geng","sequence":"first","affiliation":[{"name":"Nephrology Department, Sichuan Provincial People's Hospital, Chengdu, China"},{"name":"Medical School of University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Pu","sequence":"additional","affiliation":[{"name":"Nephrology Department, Sichuan Provincial People's Hospital, Chengdu, China"},{"name":"Medical School of University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Yang","sequence":"additional","affiliation":[{"name":"Nephrology Department, Sichuan Provincial People's Hospital, Chengdu, China"},{"name":"Medical School of University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Li","sequence":"additional","affiliation":[{"name":"Nephrology Department, Sichuan Provincial People's Hospital, Chengdu, China"},{"name":"Medical School of University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-6661","authenticated-orcid":false,"given":"Yunlin","family":"Feng","sequence":"additional","affiliation":[{"name":"Nephrology Department, Sichuan Provincial People's Hospital, Chengdu, China"},{"name":"Medical School of University of Electronic Science and Technology of China, Chengdu, China"},{"name":"The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e030919","DOI":"10.1136\/bmjopen-2019-030919","article-title":"Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis","volume":"9","author":"Zheng","year":"2019","journal-title":"BMJ Open"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1631\/jzus.B1900607","article-title":"Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects","volume":"21","author":"Song","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"R7-20250504","first-page":"374","article-title":"Experimental research progress on the mechanism of traditional Chinese medicine in the treatment of Idiopathic membranous nephropathy based on podocyte protection","volume":"18","author":"Guo","year":"2017","journal-title":"Chin J Integr Trad Western Nephrol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12882-015-0199-x","article-title":"Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study","volume":"16","author":"Liu","year":"2015","journal-title":"BMC Nephrol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12882-018-0967-5","article-title":"Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy","volume":"19","author":"Shang","year":"2018","journal-title":"BMC Nephrol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1159\/000452591","article-title":"Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-\u03baB signaling pathway","volume":"41","author":"Zhou","year":"2016","journal-title":"Kidney Blood Press Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"04","DOI":"10.1186\/s12860-020-0248-6","article-title":"Triptolide ameliorates fine particulate matter-induced podocytes injury via regulating NF-\u03baB signaling pathway","volume":"21","author":"Wan","year":"2020","journal-title":"BMC Mol Cell Biol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ptr.5987","article-title":"Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"Phytother Res"},{"key":"R13-20250504","first-page":"3399","article-title":"[Overview of hepatotoxicity studies on Tripterygium wilfordii in recent 20 years]","volume":"44","author":"Tian","year":"2019","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"R14-20250504","first-page":"3406","article-title":"[Overview of reproductive toxicity studies on Tripterygium wilfordii in recent 40 years]","volume":"44","author":"Xu","year":"2019","journal-title":"Zhongguo Zhong Yao Za Zhi"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:02:53Z","timestamp":1746316973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028842"}},"subtitle":["Protocol for an open-label randomized controlled clinical trial"],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028842","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-889263\/v1","asserted-by":"object"}]},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"2022-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}